Home

Intellectual Property

Supreme Court Affirms: High Level of Proof Needed to Invalidate A Patent

The U.S. Supreme Court issued a favorable decision in the critical case of Microsoft v. i4i, in which Microsoft challenged the “clear and convincing evidence” standard traditionally used by courts in determining whether to invalidate an issued U.S. patent.

The Role of Intellectual Property in Global Health

BIO is committed to increased access to biologic medicines for patients throughout the world. 

BIO and USPTO Trace the Journey of Biotech Inventions

BIO will be co-hosting an event with the United States Patent and Trademark Office (USPTO) to celebrate the 30th anniversary of the issuance of U.S. patent 4,259,444 to Ananda Chakrabarty following the Supreme Court case, Diamond v. Chakrabarty, which held that Chakrabarty’s bioengineered bacterium was eligible for patenting.

IP: Imperative for Innovation

Patent systems can provide an advantage to society by rewarding the development of new inventions, promoting the advancement of technology and protecting the investor.  Patents often are the most important, and sometimes only, asset of a biotech company. Patents and related rights must be obtained in a timely and predictable manner and the ability to enforce those patents is critical.

Patent Reform Passes the Senate and Moves to the House

The Patent Reform Act of 2011 would strengthen and improve our nation’s patent system, spurring innovation and job creation.

Interplay Between IP and Global Health at BIO IP Counsels Committee Spring Conference

The Biotechnology Industry Organization (BIO) will hold its Intellectual Property Counsels Committee Spring Conference and Meeting in Seattle, Washington from April 13-15.

Intellectual Property in Emerging Markets

Brenda Herschbach Jarrell and Jennifer Groves present an overview of the IP landscape in China, India, Brazil and Korea.

What Legal Issues are Presented by Biosimilars?
Hindering Progress: Gene Patent Limits Could Impede Innovation

A new federal recommendation could hinder innovations from biotechnology R&D by limiting gene patents and licenses.

Speeding Patent Processing: New Pilots Begin

The folks at the U.S. Patent and Trademark Office are trying to remedy the slow process of patent processing by erasing redundancies and increasing efficiency through various methods, all discussed — but not solved — at a recent roundtable held at USPTO headquarters in Alexandria, Va.

At Stake: Gene-Based Patents

A patent case winding its way through U.S. District Court has the potential to hinder biotechnology R&D if the judge hearing the case rules in favor of the plaintiffs, led by the American Civil Liberties Union.

Hans Sauer and Professor Chris Holman: The Role of Patents in a Pathway for the Approval of Biosimilars
BIO 2009 MEMBER SURVEY TECHNOLOGY TRANSFER AND THE BIOTECHNOLOGY INDUSTRY

The purpose of this survey was to examine the extent and importance of technology transfer and licensing activity involving biotechnology companies.

The Economic Impact of Licensed Commercialized Inventions Originating in University Research, 1996-2007
Guide to Biotechnology 2008

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

Letters, Testimony & Comments

International Patent Issues Highlighted at House Judiciary Committee Hearing: BIO Submits Biotech's Challenges
April 26 2012
  The House Judiciary Committee conducted a hearing on World IP Day on "International Patent Issues: Promoting...
Supplemental Examination: BIO Comments on Patent Reform
March 26 2012
From BIO’s perspective, Supplemental Examination may have significant benefits, because patents that undergo this process are...
AIA Oath or Declaration: BIO Comments
March 7 2012
Selected Excerpts: The vast majority of BIO’s members are small and medium sized enterprises that currently do not have products...
USPTO Genetic Testing Study: BIO's Testimony
February 17 2012
If a poor patient in Nevada doesn’t have access to an advanced molecular diagnostic test, and right across the border in California...
2012 Special 301 Report: Biotech's International IP Issues
February 14 2012
BIO has identified the following countries of interest and recommends the following for our 2011 Special 301 submission. Priority...
More Letters, Testimony & Comments →

Press Releases

Biotechnology Patenting and Intellectual Property to be Highlighted at 2012 BIO International Convention
April 18 2012
WASHINGTON, DC – (April 18, 2012) – Recent court decisions and ongoing implementation of the America...
BIO China International Conference Highlights Intellectual Property
October 4 2011
Washington, D.C. (October 4, 2011)- The Biotechnology Industry Organization (BIO) today highlights the Intellectual...
BIO Praises Final Passage of Patent Reform Legislation
September 8 2011
Washington, D.C. (September 8, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim...
BIO Praises House Passage of Patent Reform Legislation
June 23 2011
WASHINGTON, D.C. (Thursday, June 23, 2011) - Biotechnology Industry Organization (BIO) President and CEO Jim...
BIO Reaffirms Support for H.R. 1249, the Leahy-Smith America Invents Act
June 21 2011
WASHINGTON, D.C. (Tuesday, June 21, 2011) - Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood...
More Press Releases →